Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
The private group taps DualityBio for an EGFR x HER3 ADC.
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
A new phase 3 study will test Anktiva in PD-(L)1-relapsed lung cancer.
